We have investigated in malignant hyperthermia susceptible swine in vivo the effects on halothane initiation of the MH syndrome and on the established syndrome of five calcium channel blocking drugs -nijedipine. nisoldipine. diltiazem. verapamil and flunarazine. Nifedipine alone caused attenuation of halothane-initiated malignant hyperthermia to the extent of blocking onset of the syndrome in 29% of animalsfor the 60 minute period of exposure. In the face of the established malignant hyperthermia syndrome. all the drugs tested were therapeutically completely ineffective.
The pathogenesis of malignant hyperthermia (MH) rests on a cycle that results in a sustained rise in myoplasmic free calcium,u Of the many factors that may contribute to this, studies have identified in MH susceptible (MHS) swine and humans a halothane induced or enhanced dysfunction of sarcolemma involving increased calcium permeability·3.7 associated with sarcolemmal depolarisation. 8 Considered in the light of the hypothesis that the underlying functional lesion responsible for the susceptibility to MH is an abnormally low threshold calcium induced calcium release from the sarcoplasmic reticulum,9.11 such abnormalities of sarcolemmal calcium permeability could constitute the mechanism by which the syndrome is triggered. 4 In these circumstances, should the action of calcium channel blocking drugs (CCB) on skeletal muscle match their action on cardiac and smooth muscle, 12,13 it could be anticipated that pretreatment of MHS animals with CCBs would block initiation of the MH syndrome in response to their exposure to halothane. Support for such a postulate comes from in vitro studies which demonstrate both inhibition and reversal of halothane induced contractures in MHS muscle by diltiazem. 14 ,15 To test this hypothesis we have investigated in MHS swine in vivo the effects on halothane triggering of the MH syndrome of pretreatment with CCBs representative of each of the four classes of these agents. 12, 16 In view of the therapeutic implications of the in vitro studies, we investigated also the effects of these CCBs on the established syndrome.
The drugs investigated included: 1. nifedipine and nisoldipine, 2. diltiazem, 3. verapamil, 4. flunarazine.
METHODS

Animals and experimental protocol
Specially bred MHS Landrace swine of 30-50 kg weight, initially identified at the post-weaned stage by brief 'barnyard' mask exposure to halothane,17 served as the experimental animals. Under general anaesthesia and appropriate monitoring (see later) these animals were exposed to halothane inhalation and the consequent MH reaction time was observed in a protocol wherein each animal served as its own control as follows: 1. under general anaesthesia alone, 2. under general anaesthesia, with CCB treatment preceding halothane exposure.
In these circumstances administration of halothane was continued until the onset of MH or, failing this, for 60 minutes, 3. under general anaesthesia alone.
Steps in this protocol were separated by an interval of three to five days, so as to ensure complete elimination of previously administered drugs, particularly dantrolene (elimination half-life 10-12 hours). The average of times 1 and 3 was recorded as the halothane/MH reaction control time for comparison with 2 -that observed following CCB pretreatment. Experiments were conducted on groups of 2-3 pigs at a time, depending on the availability of the MHS strain of swine. Choice of pretreatment drug was random.
To test the effect of CCBs on the established MH syndrome, following establishment of anaesthesia and monitoring, MH was induced by the exposure of test animals to halothane for sufficient length of time to ensure its persistance after discontinuance of the halothane,18 whereafter the test CCB was administered IV and the effect observed.
Anaesthesia
For all experiments animals were anaesthetised initially with ketamine 10 mg/kg by intramuscular injection (dorsal neck muscles), followed shortly by IV thiopentone injection (ear vein), endotracheal intubation and N20/02 (FI02 = 0.4) administered by IPPV with a non-return circuit ventilator, the volume of ventilation being regulated to maintain Pe02 in the range 40-45 mmHg. P02 ranged from 180-220 mmHg, while mean pH during the control periods was 7.41 (SO 0.05) (n = 60). Intermittent supplemental doses of thiopentone were administered at any sign of lightening anaesthesia. Total dose of thiopentone utilised ranged from 15-25 mg/kg.
Monitoring
Carotid artery and jugular venous cannulation via cut-down in the neck provided access to blood samples for serial blood gas and acid/base assay (Radiometer), arterial and venous pressure monitoring (Hellige) and the route for fluid and drug administration. Expired C02 concentration, sampled at the endotracheal tube mount, was monitored by capnography (Morgan), ECG via skin electrodes and temperature by means of a thermistor (Ellab) inserted deep in the thigh muscle mass.
CCB pretreatment
After establishment of control conditions under anaesthesia, the test CCB was administered IV. Thereafter ten minutes was allowed for haemodynamic changes to stabilise. In view of the vasodilating effects of most CCBs, fluid loading with balanced salt solution was needed to achieve this. Thereafter test exposure to halothane 2% was commenced. After ten minutes halothane concentration was reduced to 1 %.
Dosage of drug
For both preventative pretreatment and treatment of the established syndrome, the dosage of CCBs utilised was in excess to an extent that could be tolerated -of the relevant human therapeutic dose. Doses utilised were as follows (human dose in parenthesis):
nifedipine 100 )lg/kg (20 )lg/kg) nisoldipine 6 )lg/kg (2-4 )lg/kg) diltiazem 500 )lg/kg (150 )lg/kg) verapamil 400 )lg/kg (50-100 )lg/kg) In the case of flunarazine, an oral formulation only was availaQle. A dose of 1.2 mg/kg/day (human 0.15-0.3 mg/kg/day) was administered for four days before exposure to halothane. Because of its oral formulation, the testing of flunarazine in the established syndrome was not possible.
Onset of halothane triggered MH -timing
The onset of the MH syndrome is manifested by: 17 1. muscle fasciculation proceeding to rigor, manifest in the supine pig most clearly by extension of the hind legs, 2. a gross increase in FEC02 (a manifestation of the development of metabolic and respiratory acidosis), 3. sudden tachycardia and rise in blood pressure as a manifestation of the accompanying systemic catecholamine surge, 4. progressive fulminant rise in body temperature.
In these experiments the commencement of a progressive extension of the hind limbs was recorded as the 'time of onset' of the syndrome. While the rise in FEC02 and onset of tachycardia are normally equally early (and confirmatory) signs of initiation of MH, their use in marking onset of the syndrome in this experiment was invalidated by the use of CCBs. In the former case hypotension, consequent on the combined use of CCB with halothane, resulted in an initial fall in FEC02 before the rise consequent on the syndrome became evident, while in the latter, use of CCB greatly attenuated any response to the catecholamine surge.
Time of onset of temperature rise was used as some indication of the severity and speed of the induced intramuscular reaction, as was also the rate of temperature rise.
Once triggered, the syndrome was allowed to continue until a rise in core temperature of 1-2 degrees C had occurred. Thereafter, following discontinuance of halothane, salvage of the experimental animals was ensured by administration of dantrolene sodium.
The statistical significance of differences from the control reaction were tested as follows: Of the drugs tested, pretreatment with nifedipine alone blocked halothane initiation of MH for the 60 minutes of exposure in a statistically significant proportion of test MHS swine (4/14) .
After nifedipine pretreatment administration of halothane commonly caused hypotension. Severe hypotension (MAP < 40 Torr) was manifested by three of the four pigs whose MH response to halothane was blocked by nifedipine -a statistically significant proportion compared with the incidence of a similar degree of hypotension in animals whose MH response to halothane was not blocked by nifedipine (P < 0.05).
In reactor pigs no significant attenuation was apparent following pretreatment with any CCB, in the time of onset of MH as judged by commencement of leg extension or commencement of temperature rise, nor in the rate of temperature rise -the latter averaging 1 DC per seven minutes.
None of the drugs tested displayed any therapeutic efficacy in the presence of established MH. Again, with the exception of nifedipine, our observations belie the expectation. Nifedipine alone showed a statistically significant effect in blocking halothane triggering of MH for 60 minutes but acted thus on a minority of test animals. The single instance of diltiazem blocking initiation of the syndrome, though not statistically significant, should be noted. With so Iowa rate of response, however, it was thought that proceeding to a greater number of animals would be unlikely to provide further information of phenomenological or clinical import.
Why the action of nifedipine should differ from that of other CCBs tested is open to speculation. In that nifedipine is thought to act on the postulated voltage dependant outer calcium channel gate -as against the action of the others on the inner phosphorlyation dependent gate -these findings may be construed as supporting the concept of an MH triggering mechanism based on a halothane induced, depolarisation based, increase in sarcolemmal calcium permeability. On the other hand, the apparent correlation of blocking of MH onset with extreme hypotension (systolic MAP < 40 Torr) may imply a non-specific reduction of exposure of the effector organ, the muscle, to the trigger, halothane, consequent on reduced cardiac output. We are planning to explore this postulate further in the future.
